Fabior (Stiefel Laboratories, Inc.)
Welcome to the PulseAid listing for the Fabior drug offered from Stiefel Laboratories, Inc.. This Retinoid [EPC],Retinoids [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Stiefel Laboratories, Inc. |
NON-PROPRIETARY NAME: | tazarotene |
SUBSTANCE NAME: | TAZAROTENE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Retinoid [EPC],Retinoids [Chemical/Ingredient] |
ROUTE: | TOPICAL |
DOSAGE FORM: | AEROSOL, FOAM |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2013-09-04 |
END MARKETING DATE: | 2018-09-30 |
Fabior HUMAN PRESCRIPTION DRUG Details:
Item Description | Fabior from Stiefel Laboratories, Inc. |
LABELER NAME: | Stiefel Laboratories, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 1(mg/g) |
START MARKETING DATE: | 2013-09-04 |
END MARKETING DATE: | 2018-09-30 |
PRODUCT ID: | 0145-0020_b14ce1fc-f9f3-4410-b6ee-58d5cf1a12d7 |
PRODUCT NDC: | 0145-0020 |
APPLICATION NUMBER: | NDA202428 |
Other TAZAROTENE Pharmaceutical Manufacturers / Labelers: